Skip to main content
. 2013 Feb 4;110(9):3501–3506. doi: 10.1073/pnas.1222893110

Fig. 4.

Fig. 4.

SR1 treatment inhibits tumor growth in a xenotransplantation model of imatinib-sensitive GIST. Six weeks of treatment with SR1 significantly decreased GIST882 xenograft growth compared with IgG control treatment (A). Representative images of SR1 and IgG control-treated mice are shown (B). Fluorescent microscopy was used to evaluate the presence of GFP-positive growths after animal sacrifice. White arrows denote tumor nodules (C).